Composition containing NR and / or NMN and sesamin-class compounds

A synergistic composition of NR, NMN, and sesamin compounds increases NAD concentration, improving mitochondrial function and delaying aging by enhancing NAD levels, addressing the limitations of existing precursors and sesamin's unexplored effects.

JP7594581B2Active Publication Date: 2024-12-04SUNTORY HLDG LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022521871
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-11
Filing Date
2021-05-07
Publication Date
2024-12-04
Estimated Expiration
2041-05-07

AI Technical Summary

Technical Problem

There is a lack of effective methods to increase nicotinamide adenine dinucleotide (NAD) concentration in the body, which is associated with aging and age-related pathologies, as existing precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) do not fully address this need, and sesamin's effects on NAD have not been explored.

Method used

A composition containing nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and/or their salts in combination with sesamin compounds, specifically sesamin and episesamin, to enhance NAD concentration through synergistic effects.

Benefits of technology

The composition effectively increases intracellular NAD concentration, improving mitochondrial function and delaying aging by maintaining or enhancing NAD levels, thereby addressing age-related declines in physical and mental functions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594581000001
    Figure 0007594581000001
  • Figure 0007594581000002
    Figure 0007594581000002
  • Figure 0007594581000003
    Figure 0007594581000003
Patent Text Reader

Abstract

The purpose of the present invention is to provide a composition having the effect of increasing NAD concentration. The present invention pertains to a composition containing, as active ingredients: at least one selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and salts thereof; and at least one type of sesamin or the like.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition containing one or more members selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and salts thereof, and sesamin-class compounds. [Background technology]

[0002] In recent years, in countries with a high elderly population, extending healthy lifespan has become an issue. One of the factors that shorten healthy lifespan is the decrease in nicotinamide adenine dinucleotide (NAD) in the body with age. + ) production, resulting in a decline in physical functions, etc.

[0003] Here, nicotinamide adenine dinucleotide (NAD + (hereinafter, also referred to as NAD) is a coenzyme that mediates many redox reactions in the body. It is known that NAD levels decrease during the aging process, causing defects in nuclear and mitochondrial function and resulting in many age-related pathologies. For example, Non-Patent Document 1 states that aging and aging-related diseases are caused by the accumulation of nicotinamide adenine dinucleotide (NAD) in cells. + ) levels, and NAD + It has been suggested that this is related to the decreased activity of the longevity gene sirtuin, which is an NAD deacetylase. + It has been reported that increasing NAD activates sirtuins and exerts an anti-aging effect (Non-Patent Document 2). + Intensive research is being conducted to find ingredients that are effective in preventing or improving the decline of the immune system and that can be applied to medicines, foods for specified health uses, functional foods, etc.

[0004] For example, Non-Patent Document 3 discloses that nicotinamide riboside (NR), a precursor of NAD, induces the unfolded protein response of mitochondria and the synthesis of prohibitin protein, thereby activating muscle stem cells (MuSCs) in aged mice. It also discloses that NR prevents MuSC aging in a mouse model of muscular dystrophy, that NR delays the aging of neural SCs (stem cells), and that melanocyte SCs extend the life span of mice.

[0005] In addition, Non-Patent Document 4 states that nicotinamide riboside (NR) is a NAD + It is widely used as a precursor vitamin, and a single oral dose of NR has been shown to increase blood NAD levels in humans. + It has been shown that the concentration of NMN increases in a dose-dependent manner. In addition, Non-Patent Document 5 discloses that NMN activates sirtuins, specifically, the major natural NAD + We have disclosed that the intermediate (also known as intermediate metabolite) nicotinamide mononucleotide (NMN) was administered to normal wild-type mice for 12 months and that NMN effectively alleviated age-related physiological decline in the mice without any apparent toxicity, demonstrating the great potential of NMN as an effective anti-aging intervention in humans.

[0006] On the other hand, there has been no suggestion or disclosure as to the effect of sesamin and / or episesamin in increasing nicotinamide adenine dinucleotide (NAD) levels in the body. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Imai, S. & Guarente, L. (2014) Trends Cell Biol., 24, 464-471. “NAD+ and sirtuins in aging and disease” [Non-Patent Document 2] [ PubMed ] Yoshida M, Satoh A, Lin JB, Mills KF, Sasaki Y, Rensing N, Wong M, Apte RS, Imai SI., Cell Metab. (2019) 30(2):329–342.e5. “Extracellular Vesicle-Containing eNAMPT Delays Aging and Extends Lifespan in Mice” .

Outdoor Tools3

Outdoor Tools 4

Direct Environment 5

[0008] An object of the present invention is to provide a composition that has the effect of increasing NAD concentration. [Means for solving the problem]

[0009] As a result of intensive research conducted by the present inventors to solve the above-mentioned problems, they discovered that sesamin derivatives have the effect of increasing nicotinamide adenine dinucleotide (NAD), and further that a composition containing sesamin derivatives and at least one selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and salts thereof effectively increases nicotinamide adenine dinucleotide (NAD).

[0010] The present invention relates to the following compositions: [1] A composition containing, as active ingredients, one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more sesamin-class compounds. [2] The composition described in [1] above, wherein one or more of the sesamin components is sesamin and / or episesamin. [3] The composition described in [1] or [2] above, in which the molar ratio of one or more types selected from the group consisting of NR, NMN, and salts thereof to sesamin-class compounds (one or more types selected from the group consisting of NR, NMN, and salts thereof / sesamins) is 1 to 100. [4] The composition according to any one of [1] to [3] above, wherein the total content of one or more of the sesamin-class compounds is 0.001 to 10% by weight. [5] The composition according to any one of [1] to [4] above, which increases, inhibits a decrease in, maintains, or improves a nicotinamide adenine dinucleotide (NAD) concentration. [6] The composition according to any one of [1] to [5] above, which enhances, inhibits the decline of, maintains or improves mitochondrial function. [7] The composition according to any one of [1] to [6] above, which enhances, inhibits the decline of, maintains or improves mitochondrial energy production ability. [8] The composition according to any one of [1] to [7] above, which is used for inhibiting and / or delaying aging associated with a decrease in NAD concentration. [9] The composition according to any one of [1] to [8] above, which is an anti-aging composition.

[10] The composition according to any one of the above [1] to [9], which is an oral composition.

[11] The composition according to any one of [1] to

[10] above, which is a food or drink.

[12] The composition according to any one of the above [1] to

[11] , which is labeled as "inhibiting and / or delaying aging associated with a decrease in NAD concentration" and / or "inhibiting and / or delaying cellular aging."

[13] A method for increasing nicotinamide adenine dinucleotide (NAD) concentration, comprising administering one or more members selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more sesamins.

[14] A method for increasing, inhibiting a decrease, maintaining, or improving nicotinamide adenine dinucleotide (NAD) concentration, comprising administering one or more members selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and salts thereof, and one or more sesamin analogs.

[15] Use of one or more compounds selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more sesamin derivatives for increasing nicotinamide adenine dinucleotide (NAD) concentration.

[16] Use of one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more sesamin derivatives, for increasing, inhibiting a decrease, maintaining or improving nicotinamide adenine dinucleotide (NAD) concentration. Effect of the Invention

[0011] According to the present invention, a composition having the effect of increasing nicotinamide adenine dinucleotide (NAD) concentration can be provided. [Brief description of the drawings]

[0012] [Figure 1] This is a graph showing the effect of a composition containing a sesamin / episesamin mixture (SE) (sesamin:episesamin (weight ratio = 1:1)) and NR in a molar ratio of 1:100, and SE or NR on increasing intracellular NAD concentration. [Diagram 2] This is a graph showing the effect of a composition containing a sesamin / episesamin mixture (SE) (sesamin:episesamin (weight ratio = 1:1)) and NR in a molar ratio of 1:1, and SE or NR on increasing intracellular NAD concentration. [Diagram 3] This is a graph showing the effect of a composition containing a sesamin / episesamin mixture (SE) (sesamin:episesamin (weight ratio = 1:1)) and NR in a molar ratio of 1:3.3 or 1:10, or NR, on increasing intracellular NAD concentration. [Figure 4] This is a graph showing the effect of a composition containing a sesamin / episesamin mixture (SE) (sesamin:episesamin (weight ratio = 1:1)) and NMN in a molar ratio of 1:3 or 1:10, and of SE or NMN on increasing intracellular NAD concentration. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] The composition of the present invention contains one or more types of sesamin. Sesamin compounds have the effect of increasing nicotinamide adenine dinucleotide (NAD) concentration, and have the effect of increasing, inhibiting a decrease, maintaining, or improving intracellular nicotinamide adenine dinucleotide (NAD) concentration, and are used for increasing NAD concentration, inhibiting a decrease in NAD concentration, maintaining NAD concentration, or improving NAD concentration. Increasing nicotinamide adenine dinucleotide (NAD) concentration means increasing the amount of nicotinamide adenine dinucleotide (NAD). Incidentally, NAD concentration means intracellular NAD concentration.

[0014] Sesamin compounds have the effect of increasing nicotinamide adenine dinucleotide (NAD) concentration, and are expected to contribute to the prevention or improvement of aging associated with a decrease in NAD concentration by increasing, inhibiting, maintaining, or improving NAD concentration. Aging is understood to be a phenomenon in which physical, physiological, and mental functions decline. Physical changes due to aging begin around the age of 40 after reaching maturity, and include wrinkles on the skin, hair and teeth loss, graying of hair, accumulation of fatigue and decreased recovery, decreased eyesight and hearing, decreased motor function, decreased muscle strength and activity, decreased quality of sleep, and decreased bone mass. Although aging itself cannot be considered a disease, the decline in physical and physiological functions increases the risk of so-called geriatric diseases such as arteriosclerosis, glucose and lipid metabolism disorders, neurodegeneration, osteoporosis, and cataracts, and the decline in physical functions also leads to the aging of mental functions such as memory and learning. Increasing the concentration of nicotinamide adenine dinucleotide (NAD) is effective in preventing or ameliorating aging associated with a decrease in NAD concentration.

[0015] (Sesamin group) In the present invention, sesamin analogues are a general term for compounds including sesamin and its analogues. Sesamin is one of the main lignan compounds contained in sesame. In addition to episesamin, examples of sesamin analogues include dioxabicyclo[3.3.0]octane derivatives described in JP-A-4-9331. As one or more types of sesamin analogues, one of these compounds may be used alone, or two or more types may be used. Specific examples of sesamin analogues include sesamin, episesamin, sesaminol, episesaminol, sesamol, and sesamolin, and these stereoisomers or racemates may be used alone or in mixture. In addition, metabolites of sesamin analogues (for example, those described in JP-A-2001-139579) are also sesamin analogues contained in the sesamins of the present invention, and can be used in the present invention, so long as they exhibit the effects of the present invention. In the present invention, sesamin and / or episesamin can be preferably used as one or more of the sesamins, and sesamin and episesamin can be more preferably used. When sesamin and episesamin are used, the ratio thereof is not particularly limited, but for example, the weight ratio of sesamin:episesamin is preferably 1:0.1 to 1:9, more preferably 1:0.3 to 1:3, and even more preferably 1:0.5 to 1:2.

[0016] The sesamin compounds used in the present invention are not limited by their form or production method. For example, in the case of sesamin, sesamin (called sesamin extract or purified product) extracted from sesame oil by a known method (for example, the method described in JP-A-4-9331) can be used. Commercially available sesame oil (liquid) can also be used as is. However, when sesame oil is used, the flavor peculiar to sesame oil may be evaluated as being undesirable from an organoleptic perspective, so it is preferable to use a tasteless and odorless sesamin extract (or sesamin purified product) extracted from sesame oil. In addition, when sesame oil is used, the sesamin content is low, so when a desired amount of sesamin is to be incorporated, the volume per unit dose of the formulated composition becomes too large, which may cause inconvenience in ingestion. In particular, when formulated for oral administration, the formulation (tablet, capsule, etc.) becomes too large, which causes difficulties in ingestion. Therefore, from the viewpoint of a small intake amount, it is preferable to use a sesamin extract (or sesamin purified product) from sesame oil. Sesamin compounds can also be obtained by synthesis. For example, sesamin and episesamin can be synthesized by the method of Beroza et al. (J. Am. Chem. Soc., 78, 1242 (1956)). Metabolites of sesamin and episesamin can be synthesized by the method of Urata et al. (Chem. Pharm. Bull. (Tokyo), 56 (11) 1611-2 (2008)).

[0017] Sesamin-related compounds are found in natural products and foods and beverages, have a wide dietary history, and are recognized for their high safety. With their guaranteed safety, sesamin-related compounds are ideal for continuous and long-term intake.

[0018] (Nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts) The composition of the present invention comprises one or more members selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and salts thereof. NR and NMN are intermediate metabolites of NAD. NR is converted to NMN by nicotinamide riboside kinase (NRK), and NAD + It is known that NR, NMN and salts thereof are known compounds and can be produced by known production methods, and commercially available products can also be used.

[0019] As the salt of NR and / or NMN, a pharmacologically acceptable salt can be used, for example, an acid addition salt and a base addition salt can be mentioned.Specific examples include metal salts (e.g., alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt, magnesium salt and barium salt), ammonium salt, salts with inorganic acids (e.g., salts with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and phosphoric acid), and salts with organic acids (e.g., salts with organic acids such as acetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid and p-toluenesulfonic acid).

[0020] As the salt of NR and / or NMN, a salt that can be used in foods, beverages, medicines, etc. is preferable, and examples thereof include chlorides, alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as calcium salts and magnesium salts, etc. As the salt of NR, nicotinamide riboside chloride (chloride) is preferable.

[0021] (Composition containing one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more sesamin-related compounds) The composition of the present invention contains one or more selected from the group consisting of the above nicotinamide riboside (NR), the above nicotinamide mononucleotide (NMN) and their salts, and one or more of the above sesamin compounds. The composition of the present invention contains one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts, and one or more of the above sesamin compounds as active ingredients. The composition of the present invention may be a composition for increasing nicotinamide adenine dinucleotide (NAD) concentration. In the composition of the present invention, from the viewpoint of effectively increasing the effect of increasing nicotinamide adenine dinucleotide (NAD) concentration, that is, from the viewpoint of effectively increasing the effect of increasing, inhibiting a decrease, maintaining or improving NAD concentration, the molar ratio of one or more selected from the group consisting of NR, NMN and their salts to sesamin-class compounds (one or more selected from the group consisting of NR, NMN and their salts / sesamins) is preferably 1 to 100. In addition, the molar ratio of one or more selected from the group consisting of NR, NMN and their salts to sesamin-class compounds (one or more selected from the group consisting of NR, NMN and their salts / sesamins) is more preferably 3 to 80, and even more preferably 5 to 50. In order to exert an anti-aging effect by increasing the effect of increasing nicotinamide adenine dinucleotide (NAD) concentration, that is, the effect of increasing, inhibiting a decrease, maintaining or improving NAD concentration, it is also preferable from the viewpoint of anti-aging effect to set the molar ratio of NR, NMN or their salts to sesamin-class compounds in the above-mentioned specific range in the composition of the present invention. In this specification, the amount of NR, NMN, or their salts is expressed in terms of the amount of nicotinamide riboside (NR). The weight of one or more selected from the group consisting of NR, NMN, and their salts in terms of NR is the NR-converted value of the total weight of NR, NMN, and their salts.

[0022] The total content of one or more sesamin-class compounds contained in the composition of the present invention is not particularly limited and can be set depending on the form, etc. The total content of sesamin-class compounds in the composition of the present invention is, for example, preferably 0.001% by weight or more, more preferably 0.01% by weight or more, even more preferably 0.05% by weight or more, and preferably 10% by weight or less, more preferably 5% by weight or less. In one embodiment, the total content of sesamin-class compounds in the composition is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight, even more preferably 0.05 to 5% by weight. When two or more types of sesamin-class compounds are contained, the above total content is the total content of these compounds.

[0023] The total content of one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and salts thereof contained in the composition of the present invention is not particularly limited and can be set depending on the form, etc. The total content of one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts in the composition of the present invention is, for example, preferably 0.001% by weight or more in the composition, more preferably 0.01% by weight or more, even more preferably 0.05% by weight or more, and also preferably 95% by weight or less, more preferably 80% by weight or less. In one embodiment, the total content of one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts in the composition is preferably 0.001 to 95% by weight, more preferably 0.01 to 80% by weight, and even more preferably 0.05 to 70% by weight. When two or more types of compounds selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts are contained, the total content is the total content of these.

[0024] The composition of the present invention is capable of increasing nicotinamide adenine dinucleotide (NAD) concentration, enhancing, inhibiting a decrease, maintaining or improving nicotinamide adenine dinucleotide (NAD) concentration, and enhancing, inhibiting a decrease, maintaining or improving nicotinamide adenine dinucleotide (NAD) concentration that has decreased due to aging.

[0025] NAD in the body plays an important role in promoting the expression and synthesis of molecules involved in mitochondrial function and energy production by activating sirtuins and deacetylating downstream enzymes or transcription factors. Therefore, the effect of improving, inhibiting, maintaining or improving mitochondrial function can be obtained by improving, inhibiting, maintaining or improving NAD concentration. The composition of the present invention can improve, inhibit, maintain or improve mitochondrial function. In addition, the composition of the present invention can improve, inhibit, maintain or improve mitochondrial energy production ability. In addition, the composition of the present invention has an anti-cellular aging effect.

[0026] In this specification, mitochondrial function and mitochondrial energy production capacity may be evaluated based on common knowledge in the technical field to which the present invention belongs, and the method is not particularly limited. For example, the mitochondrial function can be evaluated by continuously measuring the oxygen consumption rate (hereinafter also referred to as "OCR") used by mitochondria during ATP synthesis in the cells to be measured using an extracellular flux analyzer while adding an ATP synthase inhibitor (e.g., oligomycin and rotenone) and an uncoupler (e.g., carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP)). The evaluation items can be, for example, basal respiration, ATP production capacity, and maximum respiration, which are considered to be major indicators in the evaluation of mitochondrial function.

[0027] The composition of the present invention can be used for inhibiting and / or delaying aging, and is preferably used for inhibiting and / or delaying aging associated with a decrease in NAD concentration.

[0028] In one aspect, the composition of the present invention enhances, inhibits a decrease, maintains or improves NAD concentration, and is suitable for use in enhancing, inhibiting a decrease, maintaining or improving NAD concentration that has decreased due to aging. In one aspect, it is suitable for use in improving, inhibiting, maintaining or improving NAD concentration that has decreased due to aging in middle-aged and elderly people. Middle-aged and elderly people include elderly people. Middle-aged and elderly people may be, for example, people aged 40 years or older, and elderly people may be, for example, people aged 60 years or older or 65 years or older. The NAD concentration in animals, such as humans, can be measured by a conventional method in the technical field to which the present invention pertains. For example, the Amplite (registered trademark) Colorimetric NAD / NADH Ratio Assay Kit (AAT Bioquest) or the NAD + / NADH can be measured by measuring the intracellular NAD concentration using an NADH Quantification Colorimetric Kit (Biovision).

[0029] The composition of the present invention can be used for the treatment of conditions or diseases that can be prevented or improved by increasing, inhibiting, maintaining or improving NAD concentration. Examples of such conditions or diseases include the decline of physical, physiological and mental functions associated with aging, specifically, the occurrence of skin aging symptoms (wrinkles, sagging, loss of skin elasticity, etc.), dry skin due to aging (decrease in skin moisture retention), skin spots, freckles, rough skin, decreased or increased secretion of hormones (growth hormone, thyroid hormone, adrenal cortical hormone, sex hormone, prolactin, antidiuretic hormone, parathyroid hormone, melatonin, etc.), damage to cells (brain cells, cardiac muscle cells, etc.) by active oxygen, loss of hair and teeth, decreased eyesight and hearing, decreased motor function, decreased bone mass, decreased physical strength, decreased memory, decreased learning ability, decreased immune function, and the occurrence of geriatric diseases. As used herein, prevention includes preventing onset, delaying onset, reducing the incidence, reducing the risk of onset, etc. Amelioration of a condition or disease includes recovering a subject from a condition or disease, alleviating the symptoms of a condition or disease, ameliorating the symptoms of a condition or disease, delaying or preventing the progression of a condition or disease, etc.

[0030] The compositions of the present invention can be applied in either therapeutic (medical) or non-therapeutic (non-medical) applications, the latter being a concept that does not include medical procedures, i.e., surgery, treatment or diagnosis of humans. The composition of the present invention can be in the form of a food or drink, a medicine, a quasi-drug, a feed, etc. The composition of the present invention may be a food or drink, a medicine, a quasi-drug, a feed, etc. that is used for increasing, inhibiting a decrease, maintaining, or improving a nicotinamide adenine dinucleotide (NAD) concentration, or may be a material or preparation that is mixed with these and used. Furthermore, the composition of the present invention may be a food or drink, medicine, quasi-drug, feed, etc., which is intended to improve, inhibit the decline, maintain, or improve mitochondrial function, or to improve, inhibit the decline, maintain, or improve mitochondrial energy production ability, or may be a material or preparation to be mixed with these. The composition of the present invention can be provided in the form of a drug, for example, but is not limited to this form. The drug can be provided as a composition as it is, or as a composition containing the drug. The composition of the present invention may be either an oral composition or a non-oral composition, but is preferably an oral composition. The oral composition may be a food or drink, an oral medicine, a quasi-drug, a feed, etc., or may be contained therein. The composition of the present invention is preferably a food or drink or an oral medicine, more preferably a food or drink.

[0031] The composition of the present invention can contain at least one selected from the group consisting of NR, NMN and their salts, and at least one sesamin-class compound, as well as any additives and any components, as long as the effects of the present invention are not impaired. These additives and components can be selected according to the form of the composition, and those that can be generally used for food and beverages, medicines, quasi-drugs, feed, etc. can be used. When the composition of the present invention is used as a food and beverage, medicine, quasi-drug, feed, etc., the manufacturing method is not particularly limited, and it can be manufactured by a general method.

[0032] For example, when the composition of the present invention is made into a food or drink, in addition to at least one selected from the group consisting of NR, NMN and their salts and at least one type of sesamin, ingredients that can be used in food or drink (e.g., food ingredients, food additives used as necessary, etc.) can be blended to make various foods and drinks. The foods and drinks are not particularly limited, and examples thereof include general foods and drinks, health foods, health drinks, functional foods, foods for specified health uses, and foods and drinks for sick people. The above-mentioned health foods, functional foods, foods for specified health uses, etc. can be used in various formulation forms such as fine granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, and liquid diets.

[0033] When the composition of the present invention is used as a drug or quasi-drug, for example, at least one selected from the group consisting of NR, NMN, and their salts, one or more sesamins, a pharmacologically acceptable carrier, additives added as necessary, and the like can be mixed to produce a drug or quasi-drug in various dosage forms. Such carriers, additives, and the like may be pharmacologically acceptable and usable for drug or quasi-drug, and may include, for example, one or more of excipients, binders, disintegrants, lubricants, antioxidants, colorants, and the like. Examples of the administration (ingestion) form of the drug or quasi-drug include oral or non-oral (transdermal, transmucosal, enteral, injection, etc.) administration forms. When the composition of the present invention is used as a drug or quasi-drug, it is preferable to use an oral drug or quasi-drug. Examples of dosage forms for oral administration include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables, and the like. The drug may be a drug for non-human animals.

[0034] When the composition of the present invention is used as a feed, at least one selected from the group consisting of NR, NMN and their salts and at least one sesamin-class compound may be mixed into the feed. The feed also includes feed additives. Examples of the feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; and pet food for dogs, cats, small birds, etc.

[0035] The composition of the present invention is preferably an oral composition (a composition to be taken orally (administered orally)). The dosage (which can also be referred to as the intake amount) of the composition of the present invention is not particularly limited. The dosage of the composition of the present invention may be an amount that can obtain an effect of increasing, inhibiting a decrease, maintaining or improving nicotinamide adenine dinucleotide (NAD) concentration, and may be appropriately set depending on the dosage form, administration method, subject weight, etc.

[0036] In one embodiment, when the composition of the present invention is orally ingested or administered to a human (adult), the total dosage of sesamin-class compounds is preferably 0.5 mg or more, more preferably 1 mg or more, even more preferably 3 mg or more, and preferably 200 mg or less, more preferably 100 mg or less, and even more preferably 80 mg or less per day per 60 kg body weight. In one embodiment, the total dosage of sesamin-class compounds is preferably 0.5 to 200 mg, more preferably 1 to 100 mg, and even more preferably 3 to 80 mg per day per 60 kg body weight for a human (adult). It is preferable to ingest or administer the above amount of sesamin-class compounds once or more per day, for example, once a day or in divided doses several times (for example, 2 to 3 times). In one embodiment, it is preferable to orally ingest or administer the above amount of sesamin-class compounds to a human. In one embodiment, the composition of the present invention can be used to ingest or administer the above amount of sesamin-class compounds per day per 60 kg body weight to a human. When two or more types of sesamin-class compounds are used, the above total dosage is the total amount of these compounds. In one aspect, sesamin and / or episesamin are preferably orally ingested or administered to a human (adult) at a total dosage of sesamin and episesamin of preferably 0.5 to 200 mg, more preferably 1 to 100 mg, and even more preferably 3 to 80 mg per day per 60 kg body weight.

[0037] In one embodiment, when the composition of the present invention is orally ingested or administered to a human (adult), the total dosage of one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts is preferably 0.5 mg or more, more preferably 1 mg or more, even more preferably 3 mg or more, and preferably 20000 mg or less, more preferably 10000 mg or less, and even more preferably 8000 mg or less, in terms of NR, per 60 kg body weight per day for a human (adult). In one embodiment, the total dosage of one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts is preferably 0.5 to 20000 mg, more preferably 1 to 10000 mg, and even more preferably 3 to 8000 mg, in terms of NR, per 60 kg body weight per day for a human (adult). It is preferable to ingest or administer the above amount once or more times a day, for example, once a day or divided into several times (for example, 2 to 3 times). In one embodiment, it is preferable to orally ingest or administer to a human the above amount of one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof. In one embodiment, the composition of the present invention can be used to ingest or administer to a human the above amount of one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof per 60 kg body weight per day. The above total dosage is the total amount of two or more compounds selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof when used.

[0038] The composition of the present invention is preferably one that is continuously ingested or administered. It is expected that the above-mentioned effects of sesamin-class compounds will be enhanced by continuous ingestion or administration. In addition, it is expected that the above-mentioned effects of compounds selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof will be enhanced by continuous ingestion or administration. In one embodiment, the composition of the present invention is preferably continuously ingested or administered for at least 1 week, more preferably at least 4 weeks, even more preferably at least 8 weeks, and particularly preferably at least 12 weeks.

[0039] The composition of the present invention may be labeled with a function exhibited by improving, inhibiting a decrease, maintaining, or improving nicotinamide adenine dinucleotide (NAD) concentration. For example, the label may be labeled with one or more functions selected from the group consisting of "improving, inhibiting a decrease, or maintaining mitochondrial function," "improving, inhibiting a decrease, or maintaining mitochondrial energy production ability," "inhibiting and / or delaying aging due to a decrease in NAD concentration," "inhibiting and / or delaying cellular aging," and "inhibiting aging." In one embodiment of the present invention, the composition of the present invention is preferably a food or drink labeled with the above-mentioned label. The above-mentioned label may be a label indicating that the composition is used to obtain the above-mentioned function.

[0040] The subject (which may also be called the subject of administration) to which the composition of the present invention is ingested or administered is not particularly limited, and may be humans or non-human animals. Examples of non-human animals include industrial animals, pets, and laboratory animals. Specifically, industrial animals refer to animals that need to be raised industrially, such as livestock such as cows, horses, pigs, goats, and sheep, poultry such as chickens, ducks, quails, turkeys, and ostriches, and fish such as yellowtail, yellowtail, red sea bream, horse mackerel, carp, rainbow trout, and eels. Pets refer to so-called pets and companion animals such as dogs, cats, marmosets, small birds, and hamsters, and laboratory animals refer to animals used in research in the fields of medicine, biology, agriculture, and pharmacy, such as mice, rats, guinea pigs, beagles, miniature pigs, rhesus monkeys, and cynomolgus monkeys.

[0041] The subject to which the composition of the present invention is ingested or administered (which may also be referred to as an administration subject) is preferably a human or non-human mammal, and more preferably a human. In one embodiment, the subject of administration includes a subject who needs or desires to improve, inhibit, maintain or improve nicotine adenine dinucleotide (NAD) concentration. Examples of such subjects include middle-aged and elderly people, subjects who need or desire to improve, inhibit, maintain or improve mitochondrial function, subjects who need or desire to improve, inhibit, maintain or improve mitochondrial energy production ability, and subjects who need or desire to inhibit and / or delay aging due to a decrease in NAD concentration. Middle-aged and elderly people may be, for example, humans aged 40 years or older. In one embodiment, among middle-aged and elderly people, elderly people are preferred as subjects. Elderly people may be, for example, humans aged 60 years or older or 65 years or older. The composition of the present invention can also be used for healthy people for the purpose of preventing symptoms or diseases that can be expected to be prevented or improved by improving, inhibiting, maintaining or improving nicotinamide adenine dinucleotide (NAD) concentration.

[0042] The present invention also encompasses the following methods. A method for increasing nicotinamide adenine dinucleotide (NAD) levels by administering one or more members selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts, as well as one or more sesamin analogues. A method for increasing, inhibiting a decrease, maintaining or improving nicotinamide adenine dinucleotide (NAD) concentration by administering one or more members selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts, as well as one or more sesamin analogs. A method for improving, inhibiting a decrease, maintaining or ameliorating nicotinamide adenine dinucleotide (NAD) concentration that has decreased with age, comprising administering one or more members selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts, as well as one or more members of the sesamin family.

[0043] The present invention also encompasses the following uses: Use of one or more compounds selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more sesamin derivatives, for increasing nicotinamide adenine dinucleotide (NAD) concentration. Use of one or more compounds selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more sesamin derivatives, for increasing, inhibiting a decrease in, maintaining or improving nicotinamide adenine dinucleotide (NAD) concentration. Use of one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more sesamin-class compounds, for increasing, inhibiting, maintaining or improving nicotinamide adenine dinucleotide (NAD) levels that have decreased with age. The above-mentioned method and use may be a therapeutic method or use, or a non-therapeutic method or use. Administration of one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts together with one or more sesamin analogs makes it possible to increase, inhibit, maintain or improve nicotinamide adenine dinucleotide (NAD) concentration, thereby improving, inhibit, maintain or improve mitochondrial function, improving, inhibit, maintain or improve mitochondrial energy production ability, and inhibit and / or delay aging due to decreased NAD concentration.

[0044] In the above-mentioned method and use, the compound selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts, the sesamin-based compounds, and the preferred embodiments thereof are the same as those of the composition of the present invention described above. As one or more types of sesamins, one or more types of compounds of the sesamin-based compounds may be used. In addition, as the compound selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts, one or more types of the compounds may be used, or two or more types of the compounds may be used. In the above-mentioned method and use, it is preferable to administer (ingest) to the subject a composition containing one or more types selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts, and one or more types of sesamins, at least once a day, for example, once to several times a day (for example, 2 to 3 times a day). In the above-mentioned method and use, it is preferable to orally administer (ingest) the composition of the present invention. The above-mentioned use is preferably used in humans or non-human mammals, more preferably in humans.

[0045] In the above-mentioned method and use, it is sufficient to use an amount (which can also be called an effective amount) of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and one or more selected from the group consisting of salts thereof, and one or more sesamin compounds, which is capable of obtaining the desired effect (an effect of increasing nicotinamide adenine dinucleotide (NAD) concentration, i.e., an effect of improving, inhibiting, maintaining or improving NAD concentration, thereby improving, inhibiting, maintaining or improving mitochondrial function, improving, inhibiting, maintaining or improving mitochondrial energy production ability, and / or an effect of inhibiting and / or delaying aging due to a decrease in NAD concentration). The preferred dosage and administration target of one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more sesamin compounds are the same as those of the composition of the present invention described above. One or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and their salts, and one or more sesamin-related compounds may be administered as they are, or may be administered as a composition containing them. For example, the composition of the present invention described above may be used.

[0046] In the above-mentioned use, a composition containing one or more types of sesamin compounds and a composition containing one or more types selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and their salts are prepared separately, and the two compositions are taken at approximately the same time, or after one composition is taken while the effect of the other composition is still sustained, thereby enhancing the effects of the combination of one or more types selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and their salts with one or more types of sesamin compounds as intended by the present invention (the effect of increasing NAD concentration, i.e., the effect of improving, inhibiting a decrease, maintaining, or improving NAD concentration, thereby improving, inhibiting a decrease, maintaining, or improving mitochondrial function, improving, inhibiting a decrease, maintaining, or improving mitochondrial energy production ability, and / or the effect of inhibiting and / or delaying aging due to a decrease in NAD concentration). Therefore, kits and the like that contain a composition containing one or more types of sesamin and a composition containing one or more types selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and their salts are also included in the scope of the compositions of the present invention.

[0047] The present invention also encompasses the use of one or more members selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more sesamins, for the manufacture of the composition of the present invention. EXAMPLES

[0048] The present invention will be described in more detail below with reference to examples, although the present invention is not limited to these examples.

[0049] In the examples and comparative examples, a mixture of sesamin and episesamin (sesamin:episesamin (weight ratio) = 1:1) was used as the sesamin-episesamin mixture (SE).

[0050] Comparative Examples 1-3, Example 1: Intracellular NAD by Sesamin / Episesamin Mixture (SE) and Nicotinamide Riboside (NR)+ Concentration (intracellular NAD concentration) evaluation test Intracellular NAD + To examine the effect on concentration, 0.5 × 10 4 Hepa1-6 cells / well were seeded on a 96-well plate and cultured in DMEM medium (Nacalai Tesque, Inc., containing 10% FBS) for 96 hours under conditions of 37°C and CO2 (5%). After 96 hours of culture, the medium in each well was replaced with DMEM medium (containing 1% albumin, no FBS (Comparative Example 1)) containing no sesamin-episesamin mixture (SE) or nicotinamide riboside (NR chloride (Carbosynth Limited) was used), DMEM medium containing 0.3 μM SE (containing 1% albumin, no FBS (Comparative Example 2)), DMEM medium containing 30 μM NR (containing 1% albumin, no FBS (Comparative Example 3)), or DMEM medium containing 0.3 μM SE and 30 μM NR (containing 1% albumin, no FBS (Example 1)), and cultured for another 24 hours. The medium was then removed, and the cells in the wells were washed with D-PBS (Nacalai Tesque, Inc.), after which a lysis buffer (Amplite® Colorimetric NAD / NADH Ratio Assay Kit, AAT Bioquest) was added to recover the cell extract. Then, the intracellular NAD + The concentration of intracellular NAD was analyzed. + The protein concentration of the cell extract was measured (Pierce (registered trademark) BCA Protein Assay Kit, Thermo Scientific) and the concentration was calculated as a value per protein concentration. The significance test was performed by unpaired t-test (significance level: p<0.05, vs. the control group). The results (average of N=3) are shown in FIG. 1 (*: p<0.05).

[0051] As shown in Figure 1, intracellular NAD +The concentration increased by 2.3% in the SE 0.3 μM group in Comparative Example 2 and 3.1% in the NR 30 μM group in Comparative Example 3, compared to Comparative Example 1 (medium not containing SE and NR). On the other hand, an increase of 14.6% was observed in the combination group of SE 0.3 μM and NR 30 μM in Example 1, which was significantly greater than the simple sum (5.4%) of the increase rate due to SE 0.3 μM treatment in Comparative Example 2 and the increase rate due to NR 30 μM treatment in Comparative Example 3. From the above, it was found that intracellular NAD was increased by treatment with a combination of SE and NR at a molar ratio (SE:NR) of 1:100. + A synergistic effect of increasing the concentration was confirmed.

[0052] Comparative Examples 4 to 6, Example 2: Intracellular NAD by Sesamin / Episesamin Mixture (SE) and Nicotinamide Riboside (NR) + Concentration (intracellular NAD concentration) evaluation test Intracellular NAD + To examine the effect on concentration, 1.0×10 4 Hepa1-6 cells / well were seeded in a 96-well plate and cultured in DMEM medium (Nacalai Tesque, Inc., containing 10% FBS) for 48 hours under conditions of 37℃ and CO2 (5%). After 48 hours of culture, the medium in each well was replaced with DMEM medium (containing 1% albumin, no FBS (Comparative Example 4)) not containing sesamin-episesamin mixture (SE) and nicotinamide riboside (NR, chloride used), DMEM medium containing 10μM SE (containing 1% albumin, no FBS (Comparative Example 5)), DMEM medium containing 10μM NR (containing 1% albumin, no FBS (Comparative Example 6)), or DMEM medium containing 10μM SE and 10μM NR (containing 1% albumin, no FBS (Example 2)), and cultured for another 24 hours. The medium was then removed, and the cells in the wells were washed with D-PBS (Nacalai Tesque, Inc.), after which a lysis buffer (Amplite® Colorimetric NAD / NADH Ratio Assay Kit, AAT Bioquest) was added to recover the cell extract. Then, the intracellular NAD + The concentration of intracellular NAD was analyzed. +The protein concentration of the cell extract was measured (Pierce (registered trademark) BCA Protein Assay Kit, Thermo Scientific) and the concentration was calculated as a value per protein concentration. The results (average of N=3) are shown in Figure 2 (*: p<0.05).

[0053] Figure 2 shows that intracellular NAD + The concentration increased by 1.5% in the SE 10 μM group in Comparative Example 5 and 11.6% in the NR 10 μM group in Comparative Example 6, compared to Comparative Example 4 (medium not containing SE and NR). On the other hand, an increase of 15.7% was observed in the combination group of SE 10 μM and NR 10 μM in Example 2, which was clearly greater than the simple sum (13.1%) of the increase rate due to SE 10 μM treatment in Comparative Example 5 and the increase rate due to NR 10 μM treatment in Comparative Example 6. From the above, it was found that the intracellular NAD concentration was increased by treatment with a combination of SE and NR at a molar ratio (SE:NR) of 1:1. + A synergistic effect of increasing the concentration was confirmed.

[0054] Comparative Examples 7-9, Examples 3 and 4: Intracellular NAD by Sesamin-Episesamin Mixture (SE) and Nicotinamide Riboside (NR) + Concentration (intracellular NAD concentration) evaluation test Intracellular NAD + To examine the effect on concentration, 1.0×10 4Hepa1-6 cells were seeded onto a 96-well plate at 100 cells / well and cultured in DMEM medium (Nacalai Tesque, Inc., containing 10% FBS) at 37°C and CO2 (5%) for 48 hours. After 48 hours of culture, the medium in each well was replaced with DMEM medium (containing 1% albumin, no FBS (Comparative Example 7)) containing no sesamin / episesamin mixture (SE) or nicotinamide riboside (NR, chloride used), DMEM medium (containing 1% albumin, no FBS (Comparative Example 8)) containing 10 μM NR (containing 1% albumin, no FBS (Comparative Example 9)) containing 30 μM NR (containing 1% albumin, no FBS (Example 3)), or DMEM medium (containing 1% albumin, no FBS (Example 4)) containing 3 μM SE and 10 μM NR, and the cells were cultured for a further 24 hours. The medium was then removed, and the cells in the wells were washed with D-PBS (Nacalai Tesque, Inc.), after which a lysis buffer (Amplite® Colorimetric NAD / NADH Ratio Assay Kit, AAT Bioquest) was added to recover the cell extract. Then, the intracellular NAD + The concentration of intracellular NAD was analyzed. + The protein concentration of the cell extract was measured (Pierce (registered trademark) BCA Protein Assay Kit, Thermo Scientific) and the concentration was calculated as a value per protein concentration. The results (average of N=3) are shown in Figure 3 (*: p<0.05).

[0055] As shown in Figure 3, intracellular NAD +The concentration was increased by 11.6% in the NR 10 μM group in Comparative Example 8 and 15.5% in the NR 30 μM group in Comparative Example 9, compared to Comparative Example 7 (medium not containing SE and NR). On the other hand, an increase of 17.5% was observed in the combination group of SE 3 μM and NR 10 μM in Example 3, and an increase of 21.8% was observed in the combination group of SE 3 μM and NR 30 μM in Example 4. Here, although there is no test example treated with DEME medium containing SE 3 μM, an increase in NAD concentration of 2.3% was observed in the SE 0.3 μM group in Comparative Example 2, and an increase in NAD concentration of 1.5% was observed in the SE 10 μM group in Comparative Example 5, so it is inferred that the NAD concentration will increase at a rate equivalent to these in the SE 3 μM group. In this way, when the value obtained by simply adding the increase in NAD concentration (2.3 to 1.5%) thought to be obtained by 3 μM SE to the increase in NAD concentration in Comparative Example 8 or Comparative Example 9 is compared with the increase in NAD concentration in Examples 3 and 4, it is found that the increase in Examples 3 and 4 is clearly larger. From the above, the increase in intracellular NAD concentration by treatment with a combination of SE and NR at a molar ratio (SE:NR) of 1:3.3 or 1:10 is + A synergistic effect of increasing the concentration was confirmed.

[0056] Comparative Examples 10-12 and Example 5: Intracellular NAD by Sesamin / Episesamin Mixture (SE) and Nicotinamide Riboside (NR) + Concentration (intracellular NAD concentration) evaluation test Intracellular NAD + To examine the effect on concentration, 1.5 × 10 4HepG2 cells / well were seeded in a 96-well plate and cultured in DMEM medium (Nacalai Tesque, Inc., containing 10% FBS) for 96 hours under conditions of 37°C and CO2 (5%). After 96 hours of culture, the medium in each well was replaced with DMEM medium (containing 1% albumin, no FBS (Comparative Example 10)) without sesamin-episesamin mixture (SE) and nicotinamide riboside (NR, chloride used), DMEM medium containing 0.3 μM SE (containing 1% albumin, no FBS (Comparative Example 11)), DMEM medium containing 10 μM NR (containing 1% albumin, no FBS (Comparative Example 12)), or DMEM medium containing 0.3 μM SE and 10 μM NR (containing 1% albumin, no FBS (Example 5)), and cultured for another 24 hours. The medium was then removed, and the cells in the wells were washed with D-PBS (Nacalai Tesque, Inc.), after which a lysis buffer (Amplite® Colorimetric NAD / NADH Ratio Assay Kit, AAT Bioquest) was added to recover the cell extract. Then, the intracellular NAD + The concentration of intracellular NAD was analyzed. + The concentration was calculated as a value per protein concentration by measuring the protein concentration of the cell extract (Pierce (registered trademark) BCA Protein Assay Kit, Thermo Scientific).

[0057] Intracellular NAD + With respect to the concentration, a 5.0% increase was observed in the SE 0.3 μM group of Comparative Example 11, and no increase was observed in the NR 10 μM group of Comparative Example 12, compared to Comparative Example 10 (Cont, medium not containing SE or NR). On the other hand, an 8.0% increase was observed in the combination group of SE 0.3 μM and NR 10 μM in Example 5, which was clearly greater than the simple sum (5.0%) of the increase rate due to SE 0.3 μM treatment and the increase rate due to NR 10 μM treatment. From the above, it was found that intracellular NAD was increased by treatment with a combination of SE and NR at a molar ratio (SE:NR) of 1:33. + A synergistic effect of increasing the concentration was confirmed.

[0058] Based on the above, the composition containing sesamin / episesamin mixture and nicotinamide riboside (NR) has been shown to increase intracellular NAD + It became clear that there was a synergistic effect of increasing the concentration.

[0059] Comparative Examples 13 to 16, Examples 6 and 7: Intracellular NAD by Sesamin / Episesamin Mixture (SE) and Nicotinamide Mononucleotide (NMN) + Concentration (intracellular NAD concentration) evaluation test Intracellular NAD + To examine the effect on concentration, 2.5 × 10 4 HepG2 cells were seeded onto a 96-well plate at 100 cells / well and cultured in DMEM medium (Nacalai Tesque, Inc., containing 10% FBS) at 37°C and CO2 (5%) for 48 hours. After 48 hours of culture, the medium in each well was replaced with DMEM medium not containing sesamin / episesamin mixture (SE) or nicotinamide mononucleotide (NMN) (containing 1% albumin, without FBS (Comparative Example 13)), DMEM medium containing 10 μM SE (containing 1% albumin, without FBS (Comparative Example 14)), DMEM medium containing 30 μM NMN (containing 1% albumin, without FBS (Comparative Example 15)), DMEM medium containing 100 μM NMN (containing 1% albumin, without FBS (Comparative Example 16)), DMEM medium containing 10 μM SE and 30 μM NMN (containing 1% albumin, without FBS (Example 6)), or DMEM medium containing 10 μM SE and 100 μM NMN (containing 1% albumin, without FBS (Example 7)), and cultured for an additional 24 hours. The medium was then removed, and the cells in the wells were washed with D-PBS (Nacalai Tesque, Inc.), after which a lysis buffer (Amplite® Colorimetric NAD / NADH Ratio Assay Kit, AAT Bioquest) was added to recover the cell extract. Then, the intracellular NAD + The concentration of intracellular NAD was analyzed. +The protein concentration of the cell extract was measured (Pierce (registered trademark) BCA Protein Assay Kit, Thermo Scientific) and the concentration was calculated as a value per protein concentration. The results (average of N=3) are shown in Figure 4 (*: p<0.05).

[0060] Figure 4 shows that intracellular NAD + The concentration increased by 14.2% in the SE 10 μM group in Comparative Example 14, 18.9% in the NMN 30 μM group in Comparative Example 15, and 21.3% in the NMN 100 μM group in Comparative Example 16, compared to Comparative Example 13 (culture medium not containing SE and NR). On the other hand, an increase of 38.0% was observed in the combination group of SE 10 μM and NMN 30 μM in Example 6, which was clearly greater than the simple sum of the increase rate due to the SE 10 μM treatment in Comparative Example 14 and the increase rate due to the NMN 30 μM treatment in Comparative Example 15 (33.1%). Furthermore, an increase of 74.6% was observed in the combination group of SE 10 μM and NMN 100 μM in Example 7, which was clearly greater than the simple sum (35.5%) of the increase rate due to SE 10 μM treatment in Comparative Example 14 and the increase rate due to NMN 100 μM treatment in Comparative Example 16. From the above, the intracellular NAD was increased by treating with SE and NMN in a molar ratio of 1:3 or 1:10. + A synergistic effect of increasing the concentration was confirmed.

[0061] Based on the above, it is believed that a composition containing a combination of NMN and / or a salt thereof, which is known as an NAD intermediate metabolic product, and one or more types of sesamins (preferably a sesamin / episesamin mixture) can increase intracellular NAD, just like a composition containing a sesamin / episesamin mixture and NR. + It became clear that there was a synergistic effect of increasing the concentration.

Claims

1. The present invention comprises, as active ingredients, at least one selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and at least one sesamin-class compound; the salt is one or more selected from the group consisting of chloride, sodium salt, potassium salt, calcium salt and magnesium salt; One or more of the sesamin-class compounds are sesamin and episesamin, A composition for increasing nicotinamide adenine dinucleotide (NAD) concentration, in which the molar ratio of one or more selected from the group consisting of NR, NMN and salts thereof to sesamin-class compounds (one or more selected from the group consisting of NR, NMN and salts thereof / sesamins) is 1 to 100.

2. A pharmaceutical composition comprising as active ingredients one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more sesamin derivatives, the salt is one or more selected from the group consisting of chloride, sodium salt, potassium salt, calcium salt and magnesium salt; One or more of the sesamin-class compounds are sesamin and episesamin, A composition used for increasing, inhibiting a decrease, maintaining or improving nicotinamide adenine dinucleotide (NAD) concentration, wherein the molar ratio of one or more types selected from the group consisting of NR, NMN and salts thereof to sesamin types (one or more types selected from the group consisting of NR, NMN and salts thereof / sesamins) is 1 to 100.

3. The composition according to claim 1 or 2, wherein the total content of one or more sesamin components is 0.001 to 10% by weight.

4. The composition according to any one of claims 1 to 3, which is used for enhancing, inhibiting the decline, maintaining or improving mitochondrial function.

5. The composition according to any one of claims 1 to 4, which is used for enhancing, inhibiting a decrease in, maintaining or improving mitochondrial energy production ability.

6. The composition according to any one of claims 1 to 5, which is used for inhibiting and / or delaying aging associated with a decrease in NAD concentration.

7. The composition according to any one of claims 1 to 6, which is an anti-aging composition.

8. The composition according to any one of claims 1 to 7, which is an oral composition.

9. The composition according to any one of claims 1 to 8, which is a food or drink.

10. The composition according to any one of claims 1 to 9, which is labeled with "inhibition and / or delay of aging associated with a decrease in NAD concentration" and / or "inhibition and / or delay of cellular aging."

11. A method for increasing a nicotinamide adenine dinucleotide (NAD) concentration, comprising administering a composition containing one or more members selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more members of sesamins, the salt is one or more selected from the group consisting of chloride, sodium salt, potassium salt, calcium salt and magnesium salt; One or more of the sesamin-class compounds are sesamin and episesamin, A method (excluding medical procedures on humans) in which the molar ratio of one or more types selected from the group consisting of NR, NMN, and salts thereof to sesamin-class compounds (one or more types selected from the group consisting of NR, NMN, and salts thereof / sesamins) is 1 to 100.

12. A method for increasing, inhibiting a decrease in, maintaining, or improving a nicotinamide adenine dinucleotide (NAD) concentration, comprising administering a composition containing one or more members selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and salts thereof, and one or more sesamin-related compounds, the salt is one or more selected from the group consisting of chloride, sodium salt, potassium salt, calcium salt and magnesium salt; One or more of the sesamin-class compounds are sesamin and episesamin, A method (excluding medical procedures on humans) in which the molar ratio of one or more types selected from the group consisting of NR, NMN, and salts thereof to sesamin-class compounds (one or more types selected from the group consisting of NR, NMN, and salts thereof / sesamins) is 1 to 100.

13. Use of a composition containing one or more selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more sesamin-class compounds for increasing nicotinamide adenine dinucleotide (NAD) concentration, the salt is one or more selected from the group consisting of chloride, sodium salt, potassium salt, calcium salt and magnesium salt; One or more of the sesamin-class compounds are sesamin and episesamin, A use (excluding medical procedures on humans) in which the molar ratio of one or more types selected from the group consisting of NR, NMN, and salts thereof to sesamin-class compounds (one or more types selected from the group consisting of NR, NMN, and salts thereof / sesamins) is 1 to 100.

14. A use of a composition containing one or more members selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and salts thereof, and one or more members of sesamin-class compounds, for increasing, inhibiting a decrease in, maintaining or improving a nicotinamide adenine dinucleotide (NAD) concentration, the salt is one or more selected from the group consisting of chloride, sodium salt, potassium salt, calcium salt and magnesium salt; One or more of the sesamin-class compounds are sesamin and episesamin, A use (excluding medical procedures on humans) in which the molar ratio of one or more types selected from the group consisting of NR, NMN, and salts thereof to sesamin-class compounds (one or more types selected from the group consisting of NR, NMN, and salts thereof / sesamins) is 1 to 100.

Citation Information

Patent Citations

  • Lipid peroxide production-inhibiting agent

    JP1993051388A

  • Anti-aging agent and Anti-aging method

    WO2019054485A1